Ph 3 KEYNOTE-585 Trial in Locally Advanced Resectable GEJ Adenocarcinoma didn’t meet primary endpoint of EFS improvement July 27, 2023
Ph 3 KEYNOTE-A18 Trial Met Primary Endpoint of PFS in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer July 27, 2023
Treatment with RYBREVANT® (amivantamab-vmjw) + Chemo Resulted in Statistically Significant PFS Improvement in Patients with 1L EGFR Ex 20 Ins Mutation-Positive NSCLC July 27, 2023
Opdivo + Chemo Shows OS & PFS Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial July 19, 2023
Positive data update provided on best response to therapy with first complete response in GLORIA trial in GBM, bringing 50% of patients in expansion arm to complete or near-complete response July 19, 2023
Updates on DCR in the Part A safety lead-in of THIO-101 phase 2 trial of THIO + cemiplimab in patients with advanced NSCLC announced July 19, 2023
Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL reported July 19, 2023
New Positive Interim Ph 3 Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer Announced July 12, 2023
Datopotamab Deruxtecan Met Dual Primary Endpoint Of PFS In Patients With Advanced NSCLC in TROPION-Lung01 Phase 3 Trial July 12, 2023
Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer July 12, 2023
NEJM Publishes BRUIN Ph 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with CLL/SLL July 12, 2023
Positive final KappaMab Ph2b study results in in kappa-type R/R multiple myeloma patients announced July 12, 2023
Imfinzi + Imjudo demonstrated sustained OS benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Ph 3 trial July 5, 2023
Datopotamab deruxtecan met dual primary endpoint of PFS in patients with advanced NSCLC in TROPION-Lung01 Phase III trial July 5, 2023
Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Ph 2 Study in 1st Line Pancreatic Cancer Announced July 5, 2023
Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Avastin in GBM Announced July 5, 2023
Positive Topline Results from Ph 1/2 EPCORE™ NHL-1 Trial of Epcoritamab in Patients with R/R Follicular Lymphoma announced July 5, 2023
RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer July 5, 2023
Ongoing Double-Digit ORR observed for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial June 28, 2023
FAILED TRIAL: Ph 3 KEYNOTE-585 Trial in GEJ Adenocarcinoma didn’t meet primary endpoint of EFS June 28, 2023
Ph 3 Trial of ADCETRIS (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with 3-Year PFS of 94.9% vs Less Tolerable SoC in cHL June 28, 2023
